Overview
Monkeypox virus (MPXV) is an Orthopoxvirus first identified in 1958 in laboratory monkeys. It is endemic to Central and West Africa, with sporadic outbreaks in humans. The virus is structurally similar to variola (smallpox virus) but causes less severe illness. Human transmission occurs via contact with infected animals or humans, respiratory droplets, or contaminated objects. Two distinct clades exist: the Congo Basin clade (more virulent) and the West African clade. The 2022 global outbreak highlighted its potential for wider spread. Diagnosis involves PCR testing, and treatment includes antivirals like tecovirimat. Vaccination with JYNNEOS or ACAM2000 provides cross-protection.
Key Features
MPXV is a large, enveloped virus with a 200-kb DNA genome encoding ~190 proteins. It replicates in the cytoplasm of host cells and forms characteristic brick-shaped virions. Key proteins include A35R (immune evasion) and E8L (cell entry). The virus resists drying, enabling environmental persistence. Clinical features include fever, rash, and lymphadenopathy, with a 3–6% case-fatality rate (higher for the Congo Basin clade). Asymptomatic cases are rare. Zoonotic reservoirs include rodents (e.g., rope squirrels) and non-human primates. Unlike smallpox, MPXV has an animal reservoir, complicating eradication.
Application Areas
MPXV research focuses on understanding pathogenesis, immune responses, and antiviral development. The virus is used to model smallpox due to ethical constraints on variola research. Vaccine candidates are tested against MPXV in animal studies. Public health applications include outbreak surveillance and diagnostic kit development. B2B demand arises from pharmaceutical companies (vaccine production), diagnostic labs (test kits), and academic institutions (research reagents). Biosafety compliance is critical for all applications.
Precautions
MPXV requires BSL-3 containment for lab work. Personnel should wear gloves, gowns, N95 respirators, and eye protection. Vaccination is advised for researchers and healthcare workers. Specimens must be transported as Category B infectious substances. In outbreak settings, infected individuals should isolate, and contacts must monitor for symptoms for 21 days. Disinfection protocols include using EPA-registered hospital-grade disinfectants (e.g., bleach or hydrogen peroxide-based products). Avoid contact with wild animals in endemic regions.
B2B Procurement Guide
For research institutions, source MPXV strains from reputable repositories like ATCC or BEI Resources. Verify CAS numbers (where applicable) and strain documentation. Diagnostic kit buyers should assess sensitivity/specificity data and regulatory approvals (e.g., FDA EUA). Vaccine developers may require viral proteins (e.g., A29L, M1R) as antigens; prioritize suppliers with ISO 13485 certification. Bulk orders for antigens or inactivated virus typically range from $2,000–$10,000 per mg, depending on purity. Always confirm biosafety shipping compliance (IATA/WHO guidelines).